查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1863405

大肠癌筛检和诊断市场按类型、产品、应用和最终用户划分 - 全球预测 2025-2032

Colorectal Cancer Screening & Diagnostic Market by Type, Product, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，大肠癌筛检和诊断市场将成长至 33.5 亿美元，复合年增长率为 7.60%。

主要市场统计数据
基准年 2024 18.6亿美元
预计年份：2025年 19.9亿美元
预测年份：2032年 33.5亿美元
复合年增长率 (%) 7.60%

简明扼要而又全面地概述了影响大肠癌筛检和诊断的临床、经济和营运因素。

大肠癌仍然是癌症发病率和死亡率的主要原因之一，随着临床医生、支付方和患者寻求更便利、更准确、更经济有效的筛检和诊断方法，筛检和诊断格局正在迅速变化。过去十年，非侵入性检测、影像学和分子诊断技术的进步使临床管道更加多元化，而公共卫生政策也加强了提高高风险族群筛检率的力度。因此，该领域的相关人员不再局限于传统的胃肠病学家，而是扩展到包括基层医疗提供者、诊断实验室、门诊手术中心以及专注于数位医疗和远端病人参与的供应商在内的更广泛的群体。

变革性转变正在重塑结直肠癌筛检的临床实践、技术应用和病患管道

过去几年，我们观察到多项因素共同作用，重塑了大肠直肠癌的筛检和诊断实践。首先，病患的偏好和医疗系统容量的限制，促使人们更加关注非侵入性的居家筛检方法，进而减少对医疗机构的依赖。同时，粪便检验和分子血液检测技术的进步，旨在平衡检测的可及性和诊断性能，进一步推动了这一转变。其次，影像和内视镜平台的性能和舒适度不断提升。虽然大肠镜检查仍然是诊断的黄金标准，但CT结肠成像和增强型内视镜成像技术正越来越多地用于风险分层和作为替代诊断方案。

2025年美国关税变化对供应链、采购和临床营运的累积影响

新出台的关税和不断变化的贸易政策对结直肠癌筛检和诊断领域的相关人员有重大影响。进口关税的变化可能会增加CT扫描仪、内视镜等设备以及试剂盒、试剂等耗材的到岸成本，从而影响医院、门诊手术中心和诊断实验室的采购时间和资本支出决策。为此，医疗服务提供者和经销商可能会推迟一些非紧急采购，优先采购可更换的耗材，或重新与供应商谈判合约以维持营运预算。

关键细分洞察突显了测试方法效能、产品定位、适应症匹配度和最终用户需求驱动因素。

按检测观点分析市场，揭示了筛检和粪便检验之间微妙的共生关係。筛检检测包括血液检测和影像检查，后者包括大肠镜检查、CT结肠成像和乙状结肠镜检查。在此框架下，大肠镜检查仍是确诊和治疗性介入的主要手段。同时，CT结肠成像提供了一种创伤性较小的影像学检查方法，尤其适用于不愿接受传统大肠镜检查的患者。乙状结肠镜检查在人群筛检中的重要性有所下降，但在某些临床情况和监测通讯协定中仍然有用。血液检测正逐渐成为风险分层的辅助手段，并且与检验的预后标记结合使用时，可能会影响疾病的临床表现。

区域洞察突显全球市场中不同的采用模式、法规环境和产能限制

区域趋势对筛检和诊断策略的实施方式有显着影响。在美洲，完善的筛检计画、健全的检查室基础设施以及重视预防性医疗的支付方环境，促进了粪便检验和大肠镜检查的广泛应用；同时，私部门的创新也在加速更复杂的分子检测技术的普及。另一方面，欧洲、中东和非洲的情况则截然不同，既有的公共卫生筛检策略与资源分配不均并存。西方市场强调以指南为导向的筛检管道和集中式检测网络，而中东部分地区的医疗能力限制则促使人们优先采用非侵入性、低基础设施投入的方法来扩大筛检覆盖面。

为领先组织提供定义产品策略、合作模式和创新管道的竞争考察和商业洞察

在竞争激烈的市场环境中，成熟的医疗设备和诊断公司正采取互补策略，将产品创新与联盟建立结合。一些公司专注于改进设备平台和内视镜的人体工学设计，以提升临床疗效和手术效率。另一些公司则优先开发高灵敏度耗材，例如先进试剂和粪便DNA检测，以扩大非侵入性筛检的覆盖范围。此外，一些专业实验室和诊断Start-Ups公司正在研发新型分子检测和血液检测方法，以整合到现有的临床工作流程中，并提供可扩展的检测解决方案。

为行业领导者提供切实可行的建议，以加快技术应用、管理风险并使产品和服务与医疗保健优先事项保持一致。

产业领导者应优先考虑组合式策略，在投资高影响力设备的同时，兼顾可扩展的耗材解决方案，以实现广泛应用。透过强调模组化产品设计和灵活的服务协议，製造商可以减少医院和门诊手术中心的采购摩擦，同时提高检查室的吞吐量。同时，产生以患者疗效、成本效益和实际效用为重点的临床证据，可以增强与支付方的谈判能力，并支持将其纳入实践指南。与医保机构和卫生技术评估组织建立早期且持续的对话，也有助于加速医疗覆盖和推广应用的进程。

调查方法概述了用于得出此结论的证据综合、原始研究和检验方法。

本分析采用结构化的混合方法证据综合分析，主要基于对临床专家、实验室主任和采购人员的定性访谈，并结合对同行评审的临床文献和官方监管文件的系统性回顾。主要研究包括对医院、门诊手术中心、诊断实验室和研究机构进行深度访谈，以了解其营运限制、采购行为和临床偏好。二级资讯来源用于将临床指南、技术趋势和法规环境置于特定背景下进行解读，以确保对趋势的解释与当代实践相符。

结论概述了筛检筛检下一步工作的策略意义和优先事项。

大肠直肠癌筛检和诊断格局正朝着以患者为中心、实证医学为导向、营运整合的医疗模式转变。非侵入性检测和耗材服务有助于扩大服务覆盖范围，缓解医疗资源紧张，而影像和内视镜平台则继续提供关键的诊断和治疗能力。贸易政策和采购趋势进一步增加了策略复杂性，凸显了供应链韧性以及在地化生产和分销模式的重要性。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将人工智慧演算法整合到大肠镜影像中，以提高即时息肉检测的灵敏度
  • 液态生物检体检测在结直肠癌復发非侵入性检测与监测的临床应用
  • 多标靶粪便DNA检测作为一般风险族群筛检替代方案的市场渗透率不断提高
  • 利用基因风险分析和新型生物标记组合，扩展个人化筛检通讯协定
  • 为分散式低资源环境开发携带式肠癌筛检设备
  • 实施基于远端医疗的病人参与平台，用于远距结直肠癌筛检的导航和随访
  • 改变报销框架，扩大公共医疗保健系统中非侵入性大肠直肠癌筛检的覆盖范围
  • 诊断实验室与数位医疗公司建立策略合作伙伴关係，以整合大肠癌患者数据

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：按类型分類的结直肠癌筛检和诊断市场

  • 筛检测试
    • 血液检查
    • 影像检查
      • 大肠镜检查
      • CT结肠成像
      • 柔性乙状结肠镜检查
  • 粪便检验
    • 粪便免疫化学检测
    • 癒创木脂大便潜血试验
    • 多标靶粪便DNA检测

9. 按产品分類的大肠直肠癌筛检和诊断市场

  • 消耗品
    • 成套工具
    • 试剂
  • 装置
    • CT扫描仪
    • 内视镜检查

第十章 按应用分類的大肠直肠癌筛检和诊断市场

  • 疾病监测
  • 早期检测
  • 预后评估

第十一章 按最终用户分類的结直肠癌筛检和诊断市场

  • 门诊手术中心
  • 诊断实验室
  • 医院
  • 研究所

第十二章 各地区大肠癌筛检与诊断市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 按群体分類的大肠直肠癌筛检和诊断市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国大肠癌筛检与诊断市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Abbott Laboratories
    • AbbVie Inc.
    • Agilent Technologies, Inc.
    • Bayer AG
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • bioMerieux SA
    • Bristol-Myers Squibb Company
    • Clinical Genomics Technologies Pty Ltd.
    • Eiken Chemical Co., Ltd.
    • Epigenomics AG
    • Exact Sciences Corp.
    • F. Hoffmann-La Roche Ltd.
    • Fujifilm Holdings Corporation
    • GE HealthCare Technologies, Inc.
    • Guardant Health, Inc.
    • Hologic, Inc.
    • Illumina, Inc.
    • KARL STORZ SE & Co. KG
    • Medtronic PLC
    • Merck KGaA
    • Myriad Genetics, Inc.
    • Novartis AG
    • Novigenix SA
    • Olympus Corporation
    • Prenetics Global Limited
    • QIAGEN NV
    • Quest Diagnostics Incorporated
    • Sanofi SA
    • Siemens AG
    • Sysmex Corporation
    • Thermo Fisher Scientific Inc.
Product Code: MRR-5C6F41F5AF41

The Colorectal Cancer Screening & Diagnostic Market is projected to grow by USD 3.35 billion at a CAGR of 7.60% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.86 billion
Estimated Year [2025] USD 1.99 billion
Forecast Year [2032] USD 3.35 billion
CAGR (%) 7.60%

A concise but comprehensive overview of the evolving clinical, economic, and operational forces transforming colorectal cancer screening and diagnostics

Colorectal cancer remains a leading cause of cancer morbidity and mortality, and the screening and diagnostic landscape is evolving rapidly as clinicians, payers, and patients seek more accessible, accurate, and cost-effective approaches. Over the past decade, advances in noninvasive testing, imaging modalities, and molecular diagnostics have diversified clinical pathways, while public health initiatives have intensified efforts to increase screening uptake among at-risk populations. As a result, the ecosystem now includes a broader range of stakeholders beyond traditional gastrointestinal specialists, encompassing primary care providers, diagnostics laboratories, ambulatory surgical centers, and technology vendors focused on digital health and remote patient engagement.

Clinical practice guidelines continue to emphasize early detection and risk-appropriate screening, and this has spurred investment in technologies that reduce barriers to participation. Simultaneously, the healthcare delivery context has placed renewed emphasis on patient experience and operational efficiency, prompting providers to adopt stool-based testing and streamlined referral pathways that can reduce the burden on endoscopy suites. Regulatory frameworks and payer policies are adapting to accommodate new evidence, increasing the importance of robust clinical validation and real-world outcomes. Consequently, industry players must navigate a confluence of clinical, economic, and logistical factors to deliver solutions that align with evolving standards of care and stakeholder expectations.

In this environment, a strategic view that integrates the diversity of screening modalities, the segmentation of product types, and the variability of end-user settings is essential for identifying sustainable opportunities. The following sections examine the transformative shifts, regulatory and trade pressures, segmentation dynamics, regional nuances, competitive behavior, and actionable recommendations that together define the contemporary colorectal cancer screening and diagnostics domain.

Transformative shifts reshaping clinical practice, technology adoption, and patient pathways across colorectal cancer screening

The past several years have witnessed multiple converging shifts that are reshaping colorectal cancer screening and diagnostic practice. First, patient preference and system capacity have accelerated interest in noninvasive, home-based screening modalities that reduce dependency on facility-based procedures. This shift is complemented by technological progress in stool-based assays and blood-based molecular tests that aim to balance accessibility with diagnostic performance. Second, imaging and endoscopic platforms continue to improve in capability and comfort, where colonoscopy remains the diagnostic gold standard but CT colonography and enhanced endoscopic imaging are increasingly used for risk stratification and alternative diagnostic algorithms.

Concurrently, payer policies and quality metrics are exerting pressure on screening pathways to deliver measurable population health outcomes, prompting providers to implement organized screening programs and reminder systems. Diagnostics laboratories and instrument manufacturers are responding by enhancing automation, integrating digital reporting, and fostering interoperability with electronic health records to streamline workflows. Additionally, the emergence of precision oncology concepts is driving demand for diagnostics that support early detection, prognosis assessment, and personalized post-diagnostic monitoring. Lastly, cross-sector collaboration among clinical researchers, technology vendors, and health systems has accelerated evidence generation, enabling faster translation of promising assays into routine care. Together, these dynamics create an environment where scalability, demonstrated clinical utility, and operational integration determine which innovations achieve sustained adoption.

Cumulative implications of tariff policy changes in the United States for 2025 on supply chains, procurement, and clinical operations

Emerging tariff measures and trade policy shifts have meaningful implications for stakeholders operating in the colorectal cancer screening and diagnostics space. Changes in import duties can increase the landed cost of instruments such as CT scanners and endoscopes, as well as consumables including kits and reagents, thereby influencing procurement timing and capital expenditure decisions by hospitals, ambulatory surgical centers, and diagnostics laboratories. In response, healthcare providers and distributors may delay nonurgent purchases, prioritize replaceable consumables, or renegotiate supplier contracts to preserve operating budgets.

Moreover, tariffs can amplify supply chain fragility by incentivizing suppliers to reconfigure production footprints, pursue nearshoring, or source alternative component vendors. This reconfiguration can lead to transitional disruptions in availability and lead times. To mitigate these effects, manufacturers often accelerate localization of assembly or partner with domestic suppliers, a process that can introduce short-term cost increases but ultimately enhance resilience. Clinically, any procurement delays or cost pressures may shift the balance toward lower-resource, minimally invasive screening options that maintain throughput while limiting capital strain.

Finally, tariff-driven cost pressures also interact with reimbursement policies and payer negotiations. Health systems and diagnostics providers will need to demonstrate cost-effectiveness and operational value more rigorously when facing higher acquisition costs. As a result, organizations that proactively model scenarios, diversify supply chains, and engage in strategic sourcing partnerships will be better positioned to preserve access to advanced diagnostics while managing the financial implications of evolving trade policy.

Key segmentation insights illuminating modality performance, product positioning, application alignment, and end-user demand drivers

Analyzing the market through the lens of testing type reveals nuanced coexistence between Screening Tests and Stool Tests, where Screening Tests encompass Blood Tests and Imaging Tests, and Imaging Tests include Colonoscopy, CT Colonography, and Flexible Sigmoidoscopy. Within this structure, Colonoscopy retains primacy for definitive diagnosis and therapeutic intervention, while CT Colonography serves as a less invasive imaging alternative particularly attractive to patients averse to traditional colonoscopy. Flexible Sigmoidoscopy has diminished in prominence for population screening, yet it remains relevant in specific clinical contexts and surveillance protocols. Blood Tests are an emerging adjunct for risk stratification and may influence referral patterns when coupled with validated prognostic markers.

From a product perspective, the distinction between Consumables and Instruments shapes adoption dynamics. Consumables, comprising Kits and Reagents, are central to scaling stool-based and molecular testing programs because they support decentralized specimen collection and laboratory automation. Instruments, notably CT Scanners and Endoscopes, represent longer-term capital investments and require coordinated scheduling, maintenance, and clinician training. Consequently, organizations that offer integrated consumable supply and instrument support tend to secure deeper penetration across clinical settings.

Application segmentation-Disease Monitoring, Early Detection, and Prognosis Assessment-highlights how different technologies align with distinct clinical needs. Early Detection remains the principal driver of population screening initiatives, leveraging fecal immunochemical tests and multitarget stool DNA testing to maximize participation, whereas Disease Monitoring and Prognosis Assessment increasingly rely on molecular assays and, in some cases, blood-based biomarkers to manage post-treatment surveillance and personalize follow-up intervals. The end-user landscape composed of Ambulatory Surgical Centers, Diagnostics Laboratories, Hospitals, and Research Institutes further influences product selection; for example, diagnostics laboratories favor high-throughput kits and reagents, hospitals prioritize integrated instrument ecosystems with strong service agreements, ambulatory surgical centers emphasize throughput and patient flow for endoscopic procedures, and research institutes focus on innovative assays and clinical validation for emerging modalities.

Understanding these intersecting segmentation dimensions clarifies where investment and clinical evidence will yield the greatest impact. Products that bridge consumable convenience with robust analytical performance, supported by service models that reduce operational friction for end users across settings, will be best positioned to influence standard practice and sustain adoption.

Regional insights highlighting differentiated adoption patterns, regulatory environments, and capacity constraints across global markets

Regional dynamics exert a powerful influence on how screening and diagnostic strategies are implemented. In the Americas, organized screening programs, strong laboratory infrastructure, and payer environments that reward preventive care have supported broad use of stool-based tests and colonoscopy, while private sector innovation has accelerated adoption of higher-complexity molecular assays. Meanwhile, Europe, the Middle East & Africa presents a heterogeneous landscape where established public health screening initiatives coexist with resource variability; western European markets emphasize guideline-driven screening pathways and centralized laboratory networks, whereas parts of the Middle East & Africa face capacity constraints that favor noninvasive, low-infrastructure approaches for expanding access.

Asia-Pacific exhibits a rapid pace of technology adoption and a growing emphasis on population health initiatives, with several countries investing in endoscopy capacity and molecular diagnostics to address rising cancer burdens associated with demographic shifts. In many markets across this region, digital health solutions and mobile outreach are leveraged to increase screening uptake, and local manufacturing partnerships are increasingly common to support regional supply chains. Across all regions, the interplay between regulatory approvals, reimbursement frameworks, and clinician training determines the speed and scale of adoption. Ultimately, stakeholders seeking to expand presence or deploy new technologies must tailor strategies to regional policy priorities, infrastructure readiness, and cultural factors that influence patient participation in screening programs.

Competitive and corporate insights that define product strategies, collaboration models, and innovation pathways among leading organizations

Across the competitive landscape, established medical device manufacturers and diagnostics companies are pursuing complementary strategies that blend product innovation with alliance building. Some organizations concentrate on refining instrument platforms and endoscope ergonomics to enhance clinical outcomes and procedure efficiency, while others prioritize the development of high-sensitivity consumables such as advanced reagents and stool DNA assays aimed at broadening noninvasive screening uptake. Additionally, a cohort of specialty laboratories and diagnostic startups is advancing novel molecular assays and blood-based approaches designed to integrate with existing clinical workflows and provide scalable testing solutions.

Partnerships between device manufacturers, laboratory networks, and digital health providers have become a common pathway to accelerate market access and clinical validation. These collaborations enable bundled offerings that include test kits, laboratory processing, reporting platforms, and patient outreach tools, thereby addressing key barriers to screening adherence. Mergers and acquisitions remain a strategic lever for companies seeking to secure complementary capabilities, expand geographic reach, or internalize critical supply components. Furthermore, regulatory milestones and the generation of real-world evidence are decisive in differentiating competitive positioning, as payers and providers increasingly demand robust performance data and clear value propositions for new diagnostics. As competition intensifies, companies that can demonstrate interoperability, clinical utility, and operational support across diverse care settings will be best placed to capture long-term clinical and commercial relevance.

Actionable recommendations for industry leaders to accelerate adoption, manage risk, and align offerings with healthcare priorities

Industry leaders should prioritize a portfolio approach that balances investments in high-impact instruments with scalable consumable solutions that enable broad reach. By emphasizing modular product architectures and flexible service agreements, manufacturers can reduce procurement friction for hospitals and ambulatory surgical centers while enabling diagnostics laboratories to streamline throughput. In parallel, targeted clinical evidence generation focused on patient outcomes, cost-effectiveness, and real-world utility will strengthen negotiations with payers and support guideline inclusion. Establishing early and sustained dialogue with reimbursement authorities and health technology assessment bodies will also expedite pathways to coverage and adoption.

To mitigate trade and supply risks, organizations should diversify supplier bases and consider regional manufacturing or assembly hubs that reduce exposure to tariff volatility. Engaging in strategic partnerships with local distributors and research centers can accelerate market entry and ensure cultural alignment in outreach campaigns. Operationally, investing in digital platforms that facilitate patient reminders, remote specimen tracking, and seamless laboratory reporting will enhance adherence rates and clinician satisfaction. Finally, companies should cultivate clinician champions and collaborative pilot programs that demonstrate workflow integration, patient acceptability, and downstream clinical benefits. Together, these actions will create a resilient, evidence-backed approach to expanding the adoption of effective colorectal cancer screening and diagnostic solutions.

Research methodology outlining the evidence synthesis, primary engagement, and validation approaches used to develop the insights

The analysis synthesizes evidence from a structured mixed-methods approach combining primary qualitative engagement with clinical experts, laboratory directors, and procurement leaders alongside systematic review of peer-reviewed clinical literature and public regulatory documents. Primary research included in-depth interviews to capture operational constraints, procurement behaviors, and clinical preferences across hospitals, ambulatory surgical centers, diagnostics laboratories, and research institutes. Secondary sources were used to contextualize clinical guidelines, technological trajectories, and regulatory environments, ensuring interpretation of trends aligned with contemporary practice.

Data triangulation techniques were applied to reconcile findings from diverse information streams, and iterative validation with domain experts refined thematic conclusions and recommendations. The segmentation framework was mapped against modality characteristics, product types, clinical applications, and end-user workflows to produce actionable insights tailored to decision-making contexts. Limitations were acknowledged where data heterogeneity or regional variance reduced comparability, and sensitivity checks were conducted to ensure that conclusions reflect robust directional trends rather than single-source signals. Quality assurance procedures included expert review cycles and cross-validation of clinical claims against authoritative guideline statements to preserve factual accuracy and relevance for stakeholders.

Conclusion summarizing strategic implications and the priorities that will define the next phase of screening and diagnostic evolution

The colorectal cancer screening and diagnostics landscape is transitioning toward more patient-centric, evidence-driven, and operationally integrated models of care. Noninvasive modalities and consumable-centric offerings are expanding access and alleviating capacity constraints, while imaging and endoscopic platforms continue to offer definitive diagnostic and therapeutic capabilities. Trade policy and procurement dynamics add another layer of strategic complexity, underscoring the importance of supply chain resilience and localized approaches to manufacturing and distribution.

For stakeholders across the value chain, success will hinge on the ability to demonstrate clinical utility, operational value, and alignment with reimbursement priorities. Companies that build interoperable solutions, invest in rigorous clinical and real-world evidence, and cultivate collaborative partnerships with providers and payers will secure enduring advantage. At the same time, health systems that adopt organized screening programs, leverage digital engagement, and optimize procedural capacity can improve participation rates and downstream outcomes. The coming phase will reward those who couple technical innovation with pragmatic execution, ensuring that advances in diagnostics translate into measurable improvements in population health.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of artificial intelligence algorithms into colonoscopy imaging to improve real-time polyp detection sensitivity
  • 5.2. Clinical adoption of liquid biopsy assays for non-invasive detection and monitoring of colorectal cancer recurrence
  • 5.3. Rising market penetration of multi-target stool DNA tests as a screening alternative for average-risk populations
  • 5.4. Expansion of personalized screening protocols leveraging genetic risk profiling and novel biomarker panels
  • 5.5. Development of portable point-of-care colorectal screening devices for decentralized low-resource applications
  • 5.6. Deployment of telehealth-based patient engagement platforms for remote colorectal screening navigation and follow-up
  • 5.7. Shifts in reimbursement frameworks expanding coverage of non-invasive colorectal screening tests in public health systems
  • 5.8. Strategic partnerships between diagnostic laboratories and digital health firms to integrate colorectal cancer patient data

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Colorectal Cancer Screening & Diagnostic Market, by Type

  • 8.1. Screening Tests
    • 8.1.1. Blood Tests
    • 8.1.2. Imaging Tests
      • 8.1.2.1. Colonoscopy
      • 8.1.2.2. CT Colonography
      • 8.1.2.3. Flexible Sigmoidoscopy
  • 8.2. Stool Tests
    • 8.2.1. Fecal Immunochemical Test
    • 8.2.2. Guaiac-Based Fecal Occult Blood Test
    • 8.2.3. Multitarget Stool DNA Testing

9. Colorectal Cancer Screening & Diagnostic Market, by Product

  • 9.1. Consumables
    • 9.1.1. Kits
    • 9.1.2. Reagents
  • 9.2. Instruments
    • 9.2.1. CT Scanners
    • 9.2.2. Endoscopes

10. Colorectal Cancer Screening & Diagnostic Market, by Application

  • 10.1. Disease Monitoring
  • 10.2. Early Detection
  • 10.3. Prognosis Assessment

11. Colorectal Cancer Screening & Diagnostic Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Diagnostics Laboratories
  • 11.3. Hospitals
  • 11.4. Research Institutes

12. Colorectal Cancer Screening & Diagnostic Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Colorectal Cancer Screening & Diagnostic Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Colorectal Cancer Screening & Diagnostic Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Abbott Laboratories
    • 15.3.2. AbbVie Inc.
    • 15.3.3. Agilent Technologies, Inc.
    • 15.3.4. Bayer AG
    • 15.3.5. Becton, Dickinson and Company
    • 15.3.6. Bio-Rad Laboratories, Inc.
    • 15.3.7. bioMerieux SA
    • 15.3.8. Bristol-Myers Squibb Company
    • 15.3.9. Clinical Genomics Technologies Pty Ltd.
    • 15.3.10. Eiken Chemical Co., Ltd.
    • 15.3.11. Epigenomics AG
    • 15.3.12. Exact Sciences Corp.
    • 15.3.13. F. Hoffmann-La Roche Ltd.
    • 15.3.14. Fujifilm Holdings Corporation
    • 15.3.15. GE HealthCare Technologies, Inc.
    • 15.3.16. Guardant Health, Inc.
    • 15.3.17. Hologic, Inc.
    • 15.3.18. Illumina, Inc.
    • 15.3.19. KARL STORZ SE & Co. KG
    • 15.3.20. Medtronic PLC
    • 15.3.21. Merck KGaA
    • 15.3.22. Myriad Genetics, Inc.
    • 15.3.23. Novartis AG
    • 15.3.24. Novigenix SA
    • 15.3.25. Olympus Corporation
    • 15.3.26. Prenetics Global Limited
    • 15.3.27. QIAGEN N.V.
    • 15.3.28. Quest Diagnostics Incorporated
    • 15.3.29. Sanofi SA
    • 15.3.30. Siemens AG
    • 15.3.31. Sysmex Corporation
    • 15.3.32. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY BLOOD TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COLONOSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COLONOSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COLONOSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COLONOSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COLONOSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COLONOSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT COLONOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT COLONOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT COLONOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT COLONOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT COLONOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT COLONOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FLEXIBLE SIGMOIDOSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FLEXIBLE SIGMOIDOSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FLEXIBLE SIGMOIDOSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FLEXIBLE SIGMOIDOSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FLEXIBLE SIGMOIDOSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FLEXIBLE SIGMOIDOSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FECAL IMMUNOCHEMICAL TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FECAL IMMUNOCHEMICAL TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FECAL IMMUNOCHEMICAL TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FECAL IMMUNOCHEMICAL TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FECAL IMMUNOCHEMICAL TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FECAL IMMUNOCHEMICAL TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY GUAIAC-BASED FECAL OCCULT BLOOD TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY GUAIAC-BASED FECAL OCCULT BLOOD TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY GUAIAC-BASED FECAL OCCULT BLOOD TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY GUAIAC-BASED FECAL OCCULT BLOOD TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY GUAIAC-BASED FECAL OCCULT BLOOD TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY GUAIAC-BASED FECAL OCCULT BLOOD TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY MULTITARGET STOOL DNA TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY MULTITARGET STOOL DNA TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY MULTITARGET STOOL DNA TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY MULTITARGET STOOL DNA TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY MULTITARGET STOOL DNA TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY MULTITARGET STOOL DNA TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT SCANNERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT SCANNERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT SCANNERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT SCANNERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT SCANNERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT SCANNERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY ENDOSCOPES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY ENDOSCOPES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY ENDOSCOPES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY ENDOSCOPES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY ENDOSCOPES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY ENDOSCOPES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DISEASE MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DISEASE MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DISEASE MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DISEASE MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DISEASE MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DISEASE MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY EARLY DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PROGNOSIS ASSESSMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PROGNOSIS ASSESSMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PROGNOSIS ASSESSMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PROGNOSIS ASSESSMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PROGNOSIS ASSESSMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PROGNOSIS ASSESSMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DIAGNOSTICS LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DIAGNOSTICS LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DIAGNOSTICS LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DIAGNOSTICS LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DIAGNOSTICS LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DIAGNOSTICS LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2024 (USD MILLION)
  • TABLE 268. MIDDLE EAST COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGI